This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 85.7 kDa. The protein migrates as 90-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, Arginine, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus ACE2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Loaded SARS-CoV-2 S protein RBD, Fc Tag (Cat. No. SPD-C5255) on Protein A Biosensor, can bind Cynomolgus ACE2, His Tag (Cat. No. AC2-C52H7) with an affinity constant of 4.48 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag (Cat. No. S1N-C5257) on Protein A Biosensor, can bind Cynomolgus ACE2, His Tag (Cat. No. AC2-C52H7) with an affinity constant of 3.06 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z
